BiotechTube

Tolbutamide + Midazolam + Pexidartinib

Phase 1Completed
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Drug Interaction Potential

Conditions

Drug Interaction Potential

Trial Timeline

Feb 26, 2018 → Apr 16, 2021

NCT ID
NCT03291288

About Tolbutamide + Midazolam + Pexidartinib

Tolbutamide + Midazolam + Pexidartinib is a phase 1 stage product being developed by Daiichi Sankyo for Drug Interaction Potential. The current trial status is completed. This product is registered under clinical trial identifier NCT03291288. Target conditions include Drug Interaction Potential.

What happened to similar drugs?

8 of 15 similar drugs in Drug Interaction Potential were approved

Approved (8) Terminated (3) Active (5)
✅CefiderocolShionogiApproved
✅OnabotulinumtoxinA 145 UNT [Botox]AbbVieApproved
✅Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mLNovartisApproved
✅Oseltamivir + WarfarinRocheApproved
✅Rivaroxaban 20mg + Sotorasib 960mgAmgenApproved
✅Polyene phosphatidylcholine injection 930 mg QD + Magnesium Isoglycyrrhizinate injection 200 mg QDHaisco Pharmaceutical GroupApproved
✅AZILECT® + PlaceboLundbeckApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03291288Phase 1Completed

Competing Products

20 competing products in Drug Interaction Potential

See all competitors
ProductCompanyStageHype Score
ORIN1001Fosun PharmaPhase 1/2
32
GP404141 + NplateGEROPHARMPhase 3
34
Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg)YuhanPhase 1
29
DS-8500a + RosuvastatinDaiichi SankyoPhase 1
29
DS-1040b + ClopidogrelDaiichi SankyoPhase 1
29
EC905 + verapamilAstellas PharmaPhase 1
29
rosuvastatin + fidaxomicinAstellas PharmaPhase 1
29
enzalutamide + rifampinAstellas PharmaPhase 1
29
ASP3652 + Gemfibrozil + RepaglinideAstellas PharmaPhase 1
29
CefiderocolShionogiApproved
50
Placebo + Active Comparator #1 + Active Comparator #2 + Active Comparator #3 + Lorcaserin Dose #1 + Lorcaserin Dose #2 + Lorcaserin Dose #3EisaiPhase 1
29
Istradefylline + Phentermine 45 mgKyowa KirinPhase 1
29
Lasmiditan + Alprazolam + PlaceboEli LillyPhase 1
29
Nasal Glucagon (NG) + Glucagon IMEli LillyPhase 3
40
napabucasin + cytochrome P450 (CYP450) probe drugs or BCRP transporter substrateSumitomo PharmaPhase 1
29
Norgestimate; Ethinyl Estradiol; Folic acidJohnson & JohnsonPhase 1
29
Norgestimate; Ethinyl Estradiol; Folic acidJohnson & JohnsonPhase 1
29
Loperamide / Red Grapefruit Juice + Loperamide/ White Grapefruit Juice + Loperamide / Pink Grapefruit JuiceJohnson & JohnsonPhase 1
29
HR17031 injection + insulin glargineJiangsu Hengrui MedicinePhase 3
40
Pyrotinib Maleate + EfavirenzJiangsu Hengrui MedicinePhase 1
25